Results 41 to 50 of about 42,260 (251)

Prevalence and Risk Factors for Aspirin Resistance in Elderly Patients With Type 2 Diabetes

open access: yesInternational Journal of Gerontology, 2011
Background: Aspirin resistance in patients with diabetes is recognized. However, the prevalence and related risk factors for aspirin resistance in elderly patients with Type 2 diabetes have not been reported, which is why we undertook this study. Methods:
Lin Liu   +9 more
doaj   +1 more source

Aspirin resistance: Prevalence and clinical outcome in Egypt

open access: yesEgyptian Journal of Critical Care Medicine, 2015
Introduction: The antiplatelet drug aspirin is considered as a cornerstone in medical treatment of patients with CV or cerebrovascular diseases. Despite its use, a significant number of patients had recurrent adverse ischemic events.
Ahmed Salah   +3 more
doaj   +1 more source

Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients

open access: yesJournal of Translational Medicine, 2008
Background Our previous publication showed that 9% of patients with a history of myocardial infarction MI. could be labeled as aspirin resistant; all of these patients were aspirin resistant because of non-compliance.
Reeves Mathew   +4 more
doaj   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES

open access: yesActa Medica, 2014
Introduction: The issue of resistance to antiplatelet therapy has raised many questions in the area of neurovascular diseases. The first objective of this work was to determine the prevalence of aspirin resistance in neurovascular patients with clinical ...
Martin Vališ   +6 more
doaj   +1 more source

Aspirin strategy for secondary prevention of atherosclerotic cardiovascular diseases: A narrative review

open access: yesJournal of the Practice of Cardiovascular Sciences, 2023
Aspirin is the most used antiplatelet agent for secondary prophylaxis of atherosclerotic cardiovascular diseases. Individual variability in aspirin responsiveness has been widely reported.
Nischal N Hegde, Navin Mathew
doaj   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui   +6 more
wiley   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

open access: yesMolecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son   +13 more
wiley   +1 more source

Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI

open access: yesClinical and Applied Thrombosis/Hemostasis, 2022
Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance.
Lijie Zhang PhD, MD   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy